Explore this weekend's OTT releases across Malayalam, Tamil, and Telugu. Thrillers, action, and dramas, including Kishkindha ...
MELD’s market cap is at $2.3 million. Revuto (REVU) is up 27.9% today and shows the potential for a skyrocketing week. Last ...
Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain ...
The US Food and Drug Administration has approved revumenib (Revuforj — Syndax Pharmaceuticals) for relapsed or refractory ...
Edward White, an analyst from H.C. Wainwright, reiterated the Buy rating on Syndax Pharmaceuticals (SNDX – Research Report). The associated ...
BTIG analyst Justin Zelin has reiterated their bullish stance on SNDX stock, giving a Buy rating on November 15.Don't Miss our Black Friday ...
GlobalData on MSN8h
FDA approves Syndax’s Revuforj to treat leukaemiaThe US Food and Drug Administration (FDA) has approved Syndax Pharmaceuticals' Revuforj (revumenib) for treating relapsed or ...
Syndax Pharmaceuticals won the first FDA approval last week in a new class of medicines called menin inhibitors. The treatment, Rejuforj, will be available as soon as this month for patients with an ...
Revuforj is approved for relapsed or refractory acute leukemia with KMT2A translocation in patients aged 1 year and older. The AUGMENT-101 trial showed a 21.2% complete remission rate with a median ...
A special CBI court granted bail to four CGST officers in a ₹50 lakh bribery case, marking the release of all accused involved.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback